Impact of CTLA-4 blockade in conjunction with metronomic chemotherapy on preclinical breast cancer growth.

ABSTRACT:

Background

Although there are reports that metronomic cyclophosphamide (CTX) can be immune stimulating, the impact of its combination with anti-CTLA-4 immunotherapy for the treatment of cancer remains to be evaluated.

Methods

Murine EMT-6/P breast cancer, or its cisplatin or CTX-resistant variants, or CT-26 colon, were implanted into Balb/c mice. Established tumours were monitored for relative growth following treatment with anti-CTLA-4 antibody alone or in combination with; (a) metronomic CTX (ldCTX; 20 mg kg^-1 day^-1), b) bolus (150 mg kg^-1) plus ldCTX, or (c) sequential treatment with gemcitabine (160 mg kg^-1 every 3 days).

Results

EMT-6/P tumours responded to anti-CTLA-4 therapy, but this response was less effective when

SUBMITTER: Parra K 

PROVIDER: S-EPMC5294484 | biostudies-literature | 2017 Jan

REPOSITORIES: biostudies-literature